Table 6.
BIA-ALCL, a screening and eradication protocol for patients carrying MSSA/MRSA; antibiotic prophylaxis.
| At your center, have there been any confirmed cases of BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma)? | |||
|---|---|---|---|
| No | 69,86 % | 51 | 73 |
| Yes | 30,14 % | 22 | |
| At your center, is the National Prosthesis Registry regularly used for the inclusion of all relevant cases? | |||
| Yes | 53,42 % | 39 | 73 |
| No | 46,58 % | 34 | |
| At your center, is there a screening and eradication protocol for patients carrying MSSA/MRSA (Methicillin-Sensitive Staphylococcus Aureus and Methicillin-Resistant Staphylococcus Aureus)? | |||
| Yes | 41,67 % | 30 | 72 |
| No | 58,33 % | 42 | |
| At your center, what antibiotic prophylaxis regimen is followed in cases of conservative oncoplastic surgery? | |||
| Preoperatory single shot | 48,61 % | 35 | 72 |
| Prophylaxis within 24 h. | 16,67 % | 12 | |
| Prolonged Prophylaxis | 19,44 % | 14 | |
| No prophylaxis | 15,28 % | 11 | |
| At your center, what antibiotic prophylaxis regimen is followed in cases of mastectomy? | |||
| Preoperatory single shot | 29,17 % | 21 | 72 |
| Prophylaxis within 24 h. | 18,06 % | 13 | |
| Prolonged Prophylaxis | 47,22 % | 34 | |
| No prophylaxis | 5,56 % | 4 | |
| In case of prolonged prophylaxis, based on what criteria is the duration chosen? | |||
| Until 7 days postop | 50,00 % | 36 | 72 |
| Until 14 days postop | 1,39 % | 1 | |
| Until drains removal | 38,89 % | 28 | |
| Other (specify) | 9,72 % | 7 | |